Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (6976)	8/24/2002 12:36:45 PM
From: Icebrg	Read Replies (1) of 52153

If I have understood things correctly Forest will file based on their own US-style phase III data - using Lundbeck's data in support only. Considering the fact that the drug has been approved in Europe for other indications since 1989 there shouldn't really be any major safety concerns. I have problems seeing how FDA can turn down a safe drug in this area even if the effects are somewhat marginal. But of course - with the FDA you never know. Income - even if limited - from Europe should at least support the current valuation. The diabetic neuropathy indication does provide a very interesting upside. All IMHO of course. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next